How to Partner in the Evolving Synthetic Biology Space

December 30, 2017 | State of the Market Report

Synthetic biology has long been touted as a revolution in the bio-based materials and chemicals space. However, in spite of considerable promise, developers have had difficulties translating lab results to commercialization. Nevertheless, synthetic biology companies rank as the three highest VC funded companies in 2016. Unlike previous developers, who focused on the entire value chain from strain development to commercial scale production, newer companies have tightened focus to aid on individual steps within strain development. In light of this changing synthetic biology landscape, this report highlights promising players and outlines partnership strategies.

Coverage Areas

  • Accelerating Materials Innovation
  • Bio-based Materials and Chemicals
  • Consumer Choices in Food, Health, and Wellness

Table of Contents

  • Title page
  • The Historic Promise of Synthetic Biology
  • Assessing the Synthetic Biology Start-up Landscape
  • Picking a Partner Within Today’s Synthetic Biology Ecosystem

Lead Analyst

Gihan Hewage
Analyst

Contributors

Sara Olson

Login to View This Research

Already a Lux Client?

Sign In

Not a Lux Client?

Talk to Lux Research now and learn the benefits of becoming a member.

Lux Research

  • Helps clients find new business opportunities from emerging technologies in the physical and life sciences
  • Offers ongoing technology and market intelligence, as well as market data and consulting services
  • Now serves over 250 clients on six continents – multinational corporations, investors, governments, and SMEs
  • Has a Global reach, with offices in Boston, New York, Amsterdam, Singapore, and Tokyo
  • Combines deep technical expertise with business analysis to support strategic decisions

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 (0) 20-3460840

For APAC (Singapore)
+65 6592-6978